OVERREPRESENTATION OF THE V-KAPPA(IV) SUBGROUP IN LIGHT-CHAIN DEPOSITION DISEASE

The variability subgroup of human monoclonal kappa chains purified from urine in 3 consecutive patients with myeloma associated light chain deposition disease was determined from amino acid sequences of their first framework regions (FR1). N-glycosylation was searched for by N-glycosidase F treatment. These data together with our previously published results, ind: Icate the pathogenic potential of the rare V kappa(IV) subgroup and confirm the absence of detectable serum and urine free monoclonal light chains when they are N-glycosylated.